Published : 09 Mar 2021

---

A Japanese BioPharma has chosen Aagami to find marketing / sales / distribution partner for their Lidocaine 10% Topical Patch, which is due for US FDA approval anytime soon. The assignment is for the US market.

 

The client’s product is a Bio Equivalent product of Lidoderm® / Versatis®, however not a generic, as developed with client’s proprietary drug formulation technology.

 

·       The comparative pivotal PK study in the US confirmed the bioequivalence with Lidoderm® 

·       Indication: the treatment of PHN (postherpetic neuralgia)

 

Competitive Advantages

·       Effective Drug Delivery; Lesser dose

·       Outstanding Adhesion Property

·       Significant Dermal Safety

·       Stretchable Patch

·       Water Resistance Patch Formulation

·       Competitive Costing

 

The product is market ready uniquely positioned to succeed in the US market. A non-confidential presentation is available on request. Detailed documents are ready to be shared under a CDA.

If you are interested in this opportunity, please contact us.